Theranica’s Nerivio, a distant electrical neuromodulation (REN) product, just lately received FDA approval as a twin-use acute and preventive therapy for migraine with or with out aura in patients 12 decades of age or more mature.1 The Food and drug administration indication is supported results from a randomized placebo-controlled research published in Headache which demonstrated substantial reduction in month-to-month migraine days and other prevention conclusion details.
People who utilized Nerivio experienced a signify reduction of 4 migraine days for each thirty day period from baseline as opposed to a reduction of only 1.3 times in the placebo team, a internet therapeutic acquire of 2.7 days for each month. In addition, members also confirmed statistically important reductions from baseline in signify amount of headache days of all severities and in number of days on which they required acute migraine medicine.
“The high efficacy of Nerivio when compared to placebo in this nicely-controlled and effectively-executed review exhibits the significant prospective of REN as a reliable nonpharmacological selection to take care of and stop migraine,” Stewart J. Tepper, MD, guide author of the research, professor of neurology at the Geisel School of Medicine at Dartmouth and director of the Dartmouth Headache Center at Dartmouth Health and fitness, claimed in a statement.1
The demo consisted of a 4-7 days baseline observation stage, followed by an 8-week double-blind intervention stage, in which 248 members used both REN with Nerivio or a placebo wearable every single other day.
As entry difficulties have appeared for some individuals with migraine, products this kind of as Nerivio have emerged as supplementary, nonpharmacologic solutions. Migraine professionals, do you prescribe products for your individuals?
“Nerivio was purposely constructed to meet the serious-lifestyle demands of folks dwelling with migraine,” said Alon Ironi, Theranica CEO and co-founder Ironi, in a statement.1 “Though there is an proven motivation for powerful non-drug choices, especially for adolescents, migraine treatment needs to take care of the entire person provided the nature of this long-expression illness. With this in thoughts, we formulated an progressive wearable with a personalised wraparound care plan. Nerivio is paving a bold path forward in migraine cure and prevention for adolescents and adults. We are hopeful this expanded dual-use indicator will have a remarkable affect on mitigating the load of migraine indications and improving upon client high-quality of lifetime.”
Beforehand, in January 2021, Nerivio been given clearance as an acute procedure for migraine in the same affected person populace, based on a single-arm, multicenter research. That review included 45 participants with episodic and long-term migraine who done a check treatment with the REN and found there to be only 1 product-related adverse function (AE 2%) which was a short-term experience of suffering in the arm.2 The final results confirmed that suffering reduction and agony independence at 2 hours have been reached by 71% (28 of 39 members) and 35% (14 of 39) of members, respectively.
“Nerivio already has a perfectly-established efficacy and safety profile in acute migraine treatment method,” says Andrew Blumenfeld, MD, director of the Los Angeles Headache Middle and a co-author of the paper said in a assertion.1 “Powerful preventive procedure is vital to taking care of migraine, but it is typically underutilized. The trial information demonstrates Nerivio can now cover the full treatment spectrum and give entry to migraine prevention and aid, in particular for the adolescent populace, who have a solid preference for clinically efficient, drug-no cost remedy options. With Fda clearance of the product, its availability and possible use for preventive and acute treatment is welcome information for equally physicians and individuals.”
Nerivio is the first Food and drug administration-cleared smartphone-controlled prescription wearable machine for acute migraine treatment of episodic or chronic migraine in men and women 12 many years and older and been given a further prior acceptance in October 2020. At the time, it was only accredited for patients aged 18 many years and older.3 Its first de novo clearance was granted in May perhaps 2019, for the acute treatment of migraine with or with no aura in adults.4
Each individual Nerivio unit is good to use for 12 solutions, right after which a newly dispensed device can be presented to fill prescriptions. The device can be recycled upon the want to discard it. The prescription unit is self-utilized to the higher-arm and is made use of in the dwelling surroundings at the onset of migraine headache or aura. It gained national recognition in November 2019 after it was named to TIME Magazine’s once-a-year listing of best 100 best inventions. Nerivio is also readily available by prescription by any certified healthcare company and can be accessed on telemedicine platforms this kind of as Cove and UpScript.
1. Theranica’s Nerivio Cleared by Fda for Preventive Procedure of Migraine. Theranica. News Launch. Posted February 28, 2023. Accessed February 28, 2023. https://www.prnewswire.com/news-releases/theranicas-nerivio-cleared-by-fda-for-preventive-remedy-of-migraine-301757472.html
2. Food and drug administration approves Theranica’s Nerivio for acute remedy of migraine in adolescents. Information release. January 25, 2021. Accessed February 28, 2023. https://www.prnewswire.com/news-releases/food and drug administration-approves-theranicas-nerivio-for-acute-treatment-of-migraine-in-adolescents-301213967.html
3. Nerivio gets clearance of expanded indicator to protect long-term migraine clients. News launch. Theranica Biotherapeutics. Oct 26, 2020. Accessed February 28, 2023. prnewswire.com/news-releases/nerivio-gets-clearance-of-expanded-sign-to-cover-continual-migraine-sufferers-301159445.html
4. Food and drug administration Grants Theranica De Novo to Market Initially Smartphone-managed Acute Migraine-aid Wearable Unit. News release. Theranica. May 28, 2019. Accessed February 28, 2023. www.prnewswire.com/information-releases/food and drug administration-grants-theranica-de-novo-to-industry-1st-smartphone-controlled–acute-migraine-reduction-wearable-gadget-300857281.html